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ABSTRACT 
Plasminogen activator inhibitor type-2 (PAI-2) is a serine protease inhibitor of the fibrinolytic 
system produced predominantly by the macrophages and monocytes. It has been demonstrat-
ed that fibrinolysis regulation has a great importance in the pathogenesis of atherosclerotic 
plaques. Thus in the current investigation, we sought to determine whether Ser413/Cys poly-
morphism (rs6104) of PAI-2 gene could be associated with atherosclerosis and cardiovascular 
risk factors. Ser413/Cys polymorphism was determined by PCR-RFLP technique using Mwo I 
restriction enzyme for 184 men under 50 years of age and 216 women less than 55 years of 
age who underwent diagnostic coronary angiography. Data on the history of familial myocar-
dial infarction or other heart diseases, hypertension, and smoking habit were collected by a 
simple questionnaire. Fasting levels of blood sugar, triglycerides, total cholesterol, low-
density lipoprotein and high-density lipoprotein cholesterol levels were also measured by en-
zymatic methods. Frequencies of the Ser413 and Cys413 alleles were 0.760 and 0.240 in the 
whole population, respectively. The PAI-2 gene variant analyzed was not significantly associ-
ated with either the prevalence of premature CAD or the classical risk factors of CAD devel-
opment such as diabetes, serum cholesterol, triglycerides, low-density lipoprotein and high-
density lipoprotein cholesterol, body mass index, hypertension, familial history of heart dys-
function or smoking.  
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INTRODUCTION 
Atherosclerotic coronary artery disease 
is a complex trait that accounts for the lead-
ing cause of premature death universally. 
There are some well recognized lifestyle 
risk factors which in combination with ge-
netic factors play a key role in the patho-
genesis of CAD, especially early-onset 
form of the disease known as premature 
coronary artery disease. Meanwhile, fibri-
nolytic cascade and coagulation system in-
volvements in atherosclerosis and its car-
diovascular complications have been 
demonstrated by several studies (Ballantyne 
and Abe, 1997; Grant, 1997; Cambien, 
1999; Juhan-Vague et al., 1999; Endler and 
Mannhalter, 2003; Nicholl et al., 2006; 
Ajjan and Ariens, 2009). The fibrinolytic 
cascade by generation of plasmin from pro-
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teolysis of its zymogen helps to maintain 
the vascular endothelial homeostasis. This 
conversion is mainly catalyzed by Plasmin-
ogen activators (PAs), including urokinase 
(uPA) and tissue-type (tPA). Two specific 
serine protease inhibitors, plasminogen ac-
tivator inhibitor-1 (PAI-1) and plasminogen 
activator inhibitor-2 (PAI-2) have inhibito-
ry effects on PAs and thus possess anti-
fibrinolytic properties (Keeton et al., 1993).  
PAI–2 belongs to the serine protease in-
hibitor (serpin) superfamily and is the ma-
jor fibrinolytic inhibitor produced by the 
monocytes and macrophages while its pres-
ence has also been detected in the smooth 
muscle and vascular endothelial cells 
(Palafox-Sanchez et al., 2009). Human 
PAI-2 is a single chain protein consisting of 
415 amino acids encoded by a 1900 bp 
transcript (Medcalf and Stasinopoulos, 
2005). The PAI-2 gene is located on chro-
mosome 18q21.3 and three polymorphisms 
have been identified on its coding region so 
far including Asn120/Asp, Asn404/Lys and 
Ser413/Cys (Kruithof et al., 1995). PAI-2 
naturally has reversible conformational 
plasticity and can exist in both monomeric 
form and polymeric configuration as well; 
the latter being stabilized by disulfide 
bonds (Medcalf and Stasinopoulos, 2005). 
It seems that the additional Cys residue re-
sulting from Ser413/Cys polymorphism 
(rs6104) somehow contributes to the for-
mation of large molecular PAI-2 complexes 
(Mikus et al., 1993; Kruithof et al., 1995; 
Buyru et al., 2003; Medcalf and Stasino-
poulos, 2005). Nevertheless, functional and 
conformational outcomes of this substitu-
tion have not been resolved well. But, since 
the reduction of the fibrinolytic activity has 
been proposed to be effective in atheroscle-
rotic plaque formation (Cesari and Rossi, 
1999) and PAI-2 has an important regulato-
ry role in protective mechanisms against 
thrombosis, there might be some kind of 
association between this polymorphism and 
arterial occlusion. Hence in the present 
study, there was an attempt to determine if 
Ser413/Cys PAI-2 polymorphism has any 
important association with premature CAD 
in Southern Iran.   
MATERIALS AND METHODS 
Study population 
The study population comprised 200 pa-
tients (92 females and 108 males) and 200 
control subjects (124 females and 76 males) 
who underwent coronary angiography be-
cause of either symptoms of suspected 
premature CAD or unrelated conditions 
such as valvular heart disease or cardio-
myopathy. The studied women (aged 32-
55; mean 49.26 ± 6.32) and men (aged 21-
50; mean 47.80 ± 7.09) were all under 55 
and 50 years of age respectively. People 
were designated as premature CAD patients 
if they had ≥ 50 % stenosis in at least one 
coronary artery while the control subjects 
were those who had < 30 % stenosis in all 
their major vessels. All the premature CAD 
patients (aged 28-55; mean 49.48 ± 7.02) 
and control subjects (aged 21-55; mean 
50.15 ± 6.67) were from the same geo-
graphical region (Southern Iran) and had a 
similar socioeconomic background. All the 
cases were informed on the aims of the 
study and all the participants provided an 
informed consent. The study was approved 
by the Ethics Committee of Shiraz Univer-
sity of Medical Sciences. Information on 
cardiovascular risk factors including hyper-
tension (those with systolic/diastolic blood 
pressures higher than 140/90 mmHg or sub-
jects who were using antihypertensive med-
ications), smoking habits (cigarette and/or 
hookah), and family history of heart disease 
(incidence of coronary artery disease, myo-
cardial infarction (MI) and aortocoronary 
bypass surgery in at least one of their first 
or second degree relatives) were also col-
lected by a standardized questionnaire. 
These data were registered as a two level 
variables. The subjects who smoked at least 
one cigarette or hookah per day or were ex-
smokers were considered as smokers while 
non-smokers were defined as those who 
had never smoked. Height and weights of 
the subjects were measured in light cloth-
ing, and body mass index (BMI) was calcu-
lated as mass in kilograms divided by 
standing height in meters squared. 
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Biochemical measurements 
Venous blood samples for biochemical 
analyses (Fasting blood sugar (FBS), total 
cholesterol (TC), high-density lipoprotein 
(HDL), low-density lipoprotein (LDL) and 
triglyceride (TG)) were drawn from each 
subject after a twelve-hour fasting. Stand-
ard enzymatic assay (Pars Azmoon, diag-
nostic kits, Iran) was used to measure the 
biochemical parameters. 
 
DNA isolation and polymorphism analysis 
Genomic DNA was extracted from leu-
kocyte nuclei by salting out method (Miller 
et al., 1988). The analysis of the Ser413/Cys 
polymorphism in the PAI-2 gene was per-
formed by PCR-RFLP method. The region 
surrounding the supposed mutation site (a 
123 bp fragment) was obtained using the 
following primers: forward: 5’-ACA GTT 
TGT GGC AGA TCA TCC-3’; reverse: 5’-
AAA AAT CTT TTG CAG AAG CAG C-
3’. PCR amplification was carried out in a 
final volume of 20 μl containing 100 ng to-
tal DNA, 1.5 mM MgCl2, 1X PCR buffer, 
10 pmol each primers, 2.5 mM of each 
dNTP and 1 Units Taq DNA polymerase. 
The reaction conditions were as follows: 
initial denaturation at 94 °C for 3 minutes 
and 40 subsequent cycles of amplification 
at 94 °C for 40 S, 60 °C for 40 S, and 72 °C 
for 40 S. Finally a 5 min step at 72 °C was 
used for ending the extension. The PCR 
products were digested with MwoI re-
striction endonuclease (Fermentas) by 
overnight incubation at 37 °C and then were 
size-separated by gel electrophoresis using 
4 % (w/v) agarose. Ser413/Ser allele was 
identified as 108 and 15 bp fragments while 
the Cys413/Cys genotype was characterized 
by 78, 30 and 15 bp fragments.  
 
Statistical analysis 
Statistical analyses were performed by 
SPSS (Statistical Package for Social Sci-
ences) software, ver. 17.0 (SPSS Inc, Chi-
cago, USA). Two-sided P values less than 
0.05 were considered statistically signifi-
cant for all the analyses. Pearson’s Chi-
square test was used for Hardy–Weinberg 
equilibrium assessments and also for the 
comparison of qualitative variables. Mean-
while two-tailed Student’s t-test and analy-
sis of variance (ANOVA) were used to 
compare quantitative data. The normality of 
distribution of the investigated variables 
was assessed using the Kolmogorov–
Smirnov criterion and, where skewed (FBS 
and TG both in the whole population and in 
each of the two case/control sub-groups and 
Age, TC, HDL and LDL only in the 
case/control sub-groups), logarithmically 
transformed to reduce kurtosis.  
 
RESULTS 
A total of 413 participants were includ-
ed in this study, among which 400 individ-
uals were genotyped successfully. The  
genotype frequencies of Ser413/Ser, 
Ser413/Cys, and Cys413/Cys were 58.75 %, 
34.75 %, and 6.5 %, respectively in the 
whole population. The distribution of PAI-2 
genotypes was found to occur in Hardy-
Weinberg proportion (P=0.3788) (Table 1). 
Allelic frequency distribution of 
Ser413/Cys polymorphism in male/female 
sub-groups indicated that the Ser413 allele 
was the most prevalent allele type in pa-
tients (0.75) and controls (0.77). The patient 
and control groups were not significantly 
different with each other regarding the al-
lelic and genotypic frequencies (P>0.05). 
The distribution of genotypes between gen-
ders was not statistically significant as well 
(Table 2). 
 
Table 1: Hardy-Weinberg equilibrium test of PAI-2 Ser413/Cys polymorphism 
Genotype Observed 
Count 
Expected 
Count 
Genotype 
Frequency 
Allele Observed 
Count 
Allele  
Frequency 
X2 P
Ser413/Ser 235 231.8 0.5875 Ser413 609 0.760 0.775 0.3788
Ser413/Cys 139 145.4 0.3475      
Cys413/Cys 26 22.8 0.0650 Cys413 191 0.240   
Total 400    800    
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Table 2: Distribution of the PAI-2 genotypes among case-control and male-female subjects 
Genotype Patients, 
N (%) 
Control, 
N (%) 
X2 P Male,  
N (%) 
Female,  
N (%) 
X2 P 
Ser413/Ser 113 (56.5) 122 (61.0) 1.369 0.504 112 (60.9) 123 (56.9) 0.654 0.721 
Ser413/Cys 75 (37.5) 64 (32.0)   61 (32.1) 78 (36.1)   
Cys413/Cys 12 (6.0) 14 (7.0)   11 (6.0) 15 (6.9)   
Total 200 (100) 200 (100)   184 (100) 216 (100)   
 
 
The characteristics of the study popula-
tion are presented at Table 3. As expected, 
most of the conventional risk factors had a 
significantly higher frequency or distribu-
tion in the premature CAD patients com-
pared with the control group. The two 
groups were matched for age. Table 4 
shows the distributions of the studied risk 
factors between various genotypes. As the P 
values indicate, none of these variables had 
a significant association with PAI-2 
Ser413/Cys polymorphism.  
Table 5 and Table 6 summarize the bio-
logical parameters with different PAI-2 
genotypes in patient and control groups re-
spectively. Distributions of these variables 
were almost similar to those observed in the 
whole population group (Table 4). 
 
Table 3: Conventional risk factors in premature CAD patients and control subjects 
 Patients Controls P Value 
Age [Yr], mean (SD) 49.48 (7.02) 50.15 (6.67) 0.258 
Weight [Kg], mean (SD)  70.46 (10.96) 71.52 (12.24) 0.405 
Hypertension N (%) 83 (41.50) 59 (29.50) 0.016 
Smoker N (%) 103 (51.50) 75 (37.50) 0.007 
Familial History N (%) 46 (23.00) 37 (18.50) 0.324 
BMI [Kg/m2], mean (SD) 25.28 (3.40) 25.71 (4.33) 0.311 
log10 FBS [mg/dl], mean (SD) 2.05 (0.17) 2.02 (0.17) 0.022 
log10 TG [mg/dl], mean (SD) 2.15 (0.27) 2.08 (0.27) 0.019 
TC [mg/dl], mean (SD) 167.67 (38.23) 158.01 (42.27) 0.032 
HDL [mg/dl], mean (SD) 35.35 (9.52) 37.27 (10.32) 0.076 
LDL [mg/dl], mean (SD) 100.10 (28.04) 91.75 (32.12) 0.016 
Abbreviation: FBS = Fasting blood sugar, HDL = High density lipoprotein, LDL = Low density lipopro-
tein, mg/dl = Milligram per Deciliter, SD = Standard deviation, TC = Total cholesterol, TG = Triglycer-
ide 
 
Table 4: Risk factor profile of the studied population according to the PAI-2 different genotypes 
 Ser413/Ser Ser413/Cys Cys413/Cys P value 
Age [Yr], mean (SD) 49.11 (6.22) 50.01 (6.31) 50.23 (6.83) 0.460
Weight [Kg], mean (SD)  70.80 (11.07) 70.97 (12.25) 72.09 (12.34) 0.884
Hypertension N (%) 91 (38.72) 44 (31.65) 7 (26.92) 0.247
Smoker N (%) 107 (45.53) 55 (39.57) 16 (61.54) 0.104
Familial History N (%) 45 (19.15) 30 (21.58) 8 (30.77) 0.366
BMI [Kg/m2], mean (SD) 25.38 (4.00) 25.41 (3.72) 26.26 (3.21) 0.593
log10 FBS [mg/dl], mean (SD) 2.04 (0.17) 2.02 (0.16) 2.10 (0.19) 0.155
log10 TG [mg/dl], mean (SD) 2.08 (0.27) 2.11 (0.26) 2.17 (0.33) 0.212
TC [mg/dl], mean (SD) 158.26 (45.52) 156.31 (46.02) 160.32 (48.06) 0.783
HDL [mg/dl], mean (SD) 36.30 (10.50) 35.79 (9.20) 37.90 (8.34) 0.647
LDL [mg/dl], mean (SD) 95.03 (33.77) 90.54 (31.40) 107.27 (36.5) 0.090
Abbreviation: FBS = Fasting blood sugar, HDL = High density lipoprotein, LDL = Low density lipopro-
tein, mg/dl = Milligram per Deciliter, SD = Standard deviation, TC = Total cholesterol, TG = Triglycer-
ide 
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As shown in Table 5, there was no sig-
nificant difference among premature CAD 
patients with different genotypes for any of 
the investigated variables except a higher 
prevalence of hypertensives in the wild type 
homozygotes (Ser413/Ser). Different geno-
types of the control group were also statisti-
cally similar for the listed factors. Here, the 
only exception was the number of smokers 
which showed a significant difference be-
tween the mutant homozygotes (Cys413/ 
Cys) and the heterozygous group (Ser413/ 
Cys) (Table 6).  
 
 
Table 5: Risk factor profile of the premature CAD patients according to the PAI-2 different genotypes 
 Ser413/Ser 
(N=113) 
Ser413/Cys 
(N=75) 
Cys413/Cys 
(N=12) 
P value 
log10 Age [Yr], mean (SD) 1.69 (0. 82) 1.70 (0. 78) 1.69 (0. 91) 0.843 
Weight [Kg], mean (SD)  69.97 (10.01) 72.75 (12.19) 70.00 (11.20) 0.424 
Hypertension N (%) 56 (49.56)* 25 (33.33) 2 (16.67) 0.017 
Smoker N (%) 58 (51.33) 38 (50.67) 7 (58.33) 0.884 
Familial History N (%) 23 (20.35) 19 (25.33) 4 (33.33) 0.496 
BMI [Kg/m2], mean (SD) 25.04 (2.99) 25.55 (4.00) 25.41 (3.05) 0.627 
log10 FBS [mg/dl], mean (SD) 2.04 (0.18) 2.04 (0.13) 2.09 (0.19) 0.212 
log10 TG [mg/dl], mean (SD) 2.12 (0.30) 2.13 (0.25) 2.17 (0.30) 0.757 
log10 TC [mg/dl], mean (SD) 2.22 (0.12) 2.21 (0.11) 2.23 (0.09) 0.918 
log10 HDL [mg/dl], mean (SD) 1.55 (0.12) 1.52 (0.10) 1.56 (0.11) 0.371 
log10 LDL [mg/dl], mean (SD) 2.00 (0.17)  1.97 (0.15) 2.03 (0.22) 0.458 
Abbreviation: FBS = Fasting blood sugar, HDL = High density lipoprotein, LDL = Low density lipopro-
tein, mg/dl = Milligram per Deciliter, SD = Standard deviation, TC = Total cholesterol, TG = Triglycer-
ide 
* Significantly different from Ser413/Cys and Cys413/Cys by Pearson’s chi-square 
 
 
Table 6: Risk factor profile of the control subjects according to the PAI-2 different genotypes 
 Ser413/Ser 
(N=122) 
Ser413/Cys 
(N=64) 
Cys413/Cys 
(N=14) 
P value 
log10 Age [Yr], mean (SD) 1.69 (0.81) 1.70 (0.84) 1.71 (0.85) 0.337 
Weight [Kg], mean (SD)  71.71 (12.13) 68.88 (12.39) 73.18 (11.72) 0.107 
Hypertension N (%) 35 (28.69) 19 (29.69) 5 (35.71) 0.861 
Smoker N (%) 49 (40.16) 17 (26.56) 9 (64.29)* 0.019 
Familial History N (%) 22 (18.03) 11 (17.19) 4 (28.57) 0.597 
BMI [Kg/m2], mean (SD) 25.49 (4.86) 25.21 (3.32) 27.11 (3.27) 0.408 
log10 FBS [mg/dl], mean (SD) 2.03 (0.16) 2.00 (0.18) 2.09 (0.13) 0.073 
log10 TG [mg/dl], mean (SD) 2.03 (0.25) 2.07 (0.28) 2.15 (0.36) 0.069 
log10 TC [mg/dl], mean (SD) 2.20 (0.14) 2.19 (0.12) 2.18 (0.13) 0.538 
log10 HDL [mg/dl], mean (SD) 1.56 (0.13) 1.56 (0.11) 1.58 (0.08) 0.628 
log10 LDL [mg/dl], mean (SD) 1.96 (0.18) 1.93 (0.17) 2.01 (0.14) 0.059 
Abbreviation: FBS = Fasting blood sugar, HDL = High density lipoprotein, LDL = Low density lipopro-
tein, mg/dl = Milligram per Deciliter, SD = Standard deviation, TC = Total cholesterol, TG = Triglycer-
ide 
* Significantly different from Ser413/Cys by Pearson’s chi-square 
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DISCUSSION 
Coronary atherosclerosis is a complex 
disease, in which environmental parame-
ters, genetic factors, and interactions among 
them are all effective in its pathogenesis. 
Meanwhile, epidemiologic studies have re-
vealed the overwhelming importance of he-
reditary predisposition in a way that at least 
50 % of susceptibility to CAD is estimated 
to be hereditary (Chan and Boerwinkle, 
1994; Roberts, 2008). Since obstructive 
coronary artery disease is caused by the 
deposition of atherosclerotic plaque and 
superimposition of thrombosis on the coro-
nary artery wall, understanding the role of 
the involved genes in coagulation cascade 
and fibrinolytic system has a major im-
portance in this field (Boekholdt et al., 
2001). Fibrinolysis regulation is dependent 
mainly on a balance between plasminogen 
activators like u-PA and t-PA and their in-
hibitors such as PAI-1 and PAI-2. Up to 
now, multiple experimental studies have 
suggested a pathogenetic role for PAI-1 in 
the development of various complications 
of coronary heart disease (Carmeliet et al., 
1993; Dawson et al., 1993; Jansson et al., 
1993; Biemond et al., 1995; Mansfield et 
al., 1995; Ye et al., 1995; Fay et al., 1997; 
Devaraj et al., 2003) although this relation-
ship has not been confirmed by some other 
researches (Dawson et al., 1993; Ye et al., 
1995; Ridker et al., 1997; Hubacek et al., 
2010). To the best of our knowledge, there 
were only two studies which have per-
formed an association study between PAI-2 
Ser413/Cys polymorphism and coronary ar-
tery atheroma and MI in the literature. Foy 
and Grant (1997) assessed the association 
between PAI-2 variants and the extent of 
coronary atheroma in 333 Caucasian MI 
patients compared with 286 healthy volun-
teers, but no significant association has 
been reported by them. Nevertheless, in the 
other report Buyru and colleagues (2003) 
have found a statistically significant associ-
ation between Ser413/Ser genotype and MI 
in a case-control study consisting of 45 MI 
patients and 20 healthy subjects. Moreover, 
McCarthy et al. (2004) conducted a high-
throughput SNP association study to identi-
fy the target genes associated with prema-
ture coronary artery disease.  They screened 
210 different polymorphisms among 110 
candidate genes from 418 premature CAD 
patients and found significant associations 
only with SNPs in thrombospondin-2 
(THBS2), thrombospondin-4 (THBS4) and 
plasminogen activator inhibitor-2. 
The present study was conducted on 
400 Caucasian participants from Southern 
Iran but the results obtained here failed to 
demonstrate an association between rs6104 
SNP of the PAI-2 gene and the premature 
CAD. The discrepancy observed between 
the result of the current investigation and 
that of the Buyru et al.’s (2003) study might 
have partly resulted from the differences 
existed between the designs of these two 
studies. Unlike the studies of Foy and Grant 
(1997) and Buyru et al. (2003) which had a 
comparison group instead of a true control 
group, our study possessed objective angio-
graphic information for not only CAD pa-
tients but also for control subjects. Lack of 
objective angiographic information may 
cause to observe an unreal association be-
tween the mutation and the disease (Girelli 
et al., 1998). Additionally, Buyru and col-
leagues (2003) included only MI survivors 
as the patient group. Limiting the patient 
group to such a phenotype is too selective 
and rules out those who have not survived 
from MI. This could contribute to un-
derrepresentation of the mutation effect 
(Girelli et al., 1998). To reduce the proba-
bility of spurious results, a control group 
with angiographically documented absence 
of premature CAD is provided in our study. 
Finally Buyru et al. (2003) found a signifi-
cant association between MI and PAI-2 
polymorphism by analyzing a quite low 
sample size (45 patients and 20 controls). 
The total number of subjects studied here 
(400 patients and controls) had the same 
problem statistically but in a lesser extent. 
Thus, a larger sample population should be 
examined to confirm the relationship be-
tween PAI-2 polymorphisms and the prem-
ature CAD. However, variations in the ge-
netic backgrounds of the investigated popu-
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lations may also account for this incon-
sistency.   
In addition to the low sample size, the 
present study had other limitations. For ex-
ample, the effects of genetic variants of 
PAI-2 on protein function and its circulat-
ing level or production have not been inves-
tigated. Moreover this is a retrospective 
case-control study which assessed only one 
polymorphism of PAI-2. Investigations of 
other SNPs by prospective studies are 
needed to evaluate more accurately the role 
of PAI-2 polymorphisms in the pathogene-
sis of premature coronary artery disease.  
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